LENZ Therapeutics, Inc. LENZ R2K
Healthcare · Biotechnology · United States
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
READ MORE ›$7.78
-73.36% 1Y
Market & Price
Market Cap
$243.94M
Current Price
$7.78
High / Low (52W)
$49.05 / $6.65
Beta
1.67
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$7.86
Price to Book
0.99
P/S
11.62
EV/EBITDA
0.12
Dividend Yield
-
Profitability & Returns
ROCE
-32.01%
ROE
-49.71%
ROA
-31.22%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-1.32
EPS (TTM)
$-3.64
Balance Sheet & Liquidity
Debt/Equity
0.27
Quick Ratio
10.11
Current Ratio
10.40
Debt
$673.00K
Total Assets
$305.88M
Current Assets
$301.41M
Working Capital
$280.23M
Ownership
Promoter Holding
2.65%
Chg in Prom Hold
-
FII / Inst Holding
107.78%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$-13.77M
Total Revenue (TTM)
$20.99M
EBITDA
$-117.98M
Free Cash Flow
$-48.81M
Operating Cash Flow
$-86.70M
Shares Outstanding
31.35M
Gross Margin
92.88%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
8.37%
Profit 5Y
-219.89%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -219.9% CAGR over 5 years.
- Trading 84.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LENZ LENZ Therapeutics, Inc. R2K | 7.78 | - | $243.94M | - | -32.01% | -49.71% | 8.37% | -219.89% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 5.00M | 12.50M | 1.59M | 1.90M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 1.08M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 825.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.93M | 21.86M | 31.39M | 39.63M | 44.96M |
| Operating Income | -1.29M | -3.76M | -9.37M | -17.53M | -14.60M | -25.96M | -26.78M | -26.15M | -12.62M | -14.96M | -19.86M | -16.09M | -14.35M | -12.95M | -16.93M | -16.86M | -18.89M | -38.46M | -44.13M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -16.89M | -16.84M | -18.76M | -38.36M | -44.02M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.62M | -14.41M | -16.70M | -35.89M | -41.49M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 500.00K | 0 | 2.00K | - |
| Net Income | -1.31M | -3.38M | -19.71M | -17.53M | -14.59M | -25.84M | -25.94M | -24.68M | -12.67M | -14.73M | -18.88M | -16.65M | -10.25M | -10.21M | -14.62M | -14.91M | -16.70M | -35.90M | -41.49M |
| Diluted EPS | - | - | - | -3.45 | -0.28 | -0.48 | -0.48 | -0.45 | -6.50 | -7.53 | -9.62 | -3.53 | -0.40 | -0.38 | -0.53 | -0.53 | -0.59 | -1.16 | -1.32 |
| R&D Expense | 423.00K | 2.31M | 5.38M | 12.67M | 8.68M | 18.25M | 17.78M | 18.30M | 10.32M | 12.64M | 17.00M | 10.54M | 6.95M | 6.45M | 5.82M | 9.06M | 3.79M | - | 0 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 15.00M | 0 | 0 | 19.09M |
| Cost of Revenue | - | - | - | - | 0 | 418.00K |
| Gross Profit | - | - | - | - | 0 | 18.67M |
| Operating Expenses | - | - | 25.48M | 72.43M | 58.61M | 109.81M |
| Operating Income | -13.50M | -60.44M | -10.48M | -72.43M | -58.61M | -91.14M |
| EBITDA | - | - | -10.47M | -72.41M | -58.55M | -90.85M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | -10.46M | -70.15M | -49.77M | -81.62M |
| Tax Provision | - | - | 347.00K | -179.00K | 1.00K | 502.00K |
| Net Income | -68.37M | -70.76M | -10.81M | -69.97M | -49.77M | -82.13M |
| Diluted EPS | - | -2.45 | -0.42 | -2.74 | -2.34 | -2.85 |
| R&D Expense | 9.12M | 37.93M | 72.79M | 59.50M | 29.80M | 18.67M |
Compounded Sales Growth
| 5 Years: | 8.37% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -219.89% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -73.36% |
| 6 Months: | -73.96% |
| 3 Months: | -42.33% |
| 1 Month: | -14.03% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 22.56M | - | 46.95M | 70.38M | 215.30M | 305.88M |
| Current Assets | - | - | - | 46.64M | 67.24M | 211.92M | 301.41M |
| Cash & Equivalents | - | 19.78M | - | 44.44M | 35.14M | 20.16M | 25.18M |
| Inventory | - | - | - | - | - | 0 | 2.94M |
| Receivables | - | - | - | - | - | 0 | 329.00K |
| Total Liabilities | - | 32.36M | - | 71.12M | 163.09M | 11.22M | 21.54M |
| Current Liabilities | - | 32.05M | - | 9.50M | 18.51M | 10.41M | 21.19M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 250.00K | 329.00K | 1.38M | 815.00K |
| Total Equity | -2.22M | -65.41M | - | -24.17M | -92.71M | 204.08M | 284.34M |
| Shares Outstanding | - | - | - | 25.53M | 25.53M | 27.53M | 31.34M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.72M | - | -4.09M | -60.38M | -59.39M | -69.17M |
| Investing Cash Flow | -1.54M | - | -37.00K | -29.62M | -154.48M | -75.67M |
| Financing Cash Flow | 30.08M | - | 30.26M | 80.70M | 199.00M | 149.75M |
| Capital Expenditure | -1.54M | - | -37.00K | -30.00K | -468.00K | -827.00K |
| Free Cash Flow | -10.27M | - | -4.13M | -60.41M | -59.86M | -70.00M |
| Net Change in Cash | - | - | 26.13M | -9.30M | -14.87M | 4.91M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 97.8% |
| Operating Margin % | - | - | -69.9% | - | - | -477.5% |
| Net Margin % | - | - | -72.1% | - | - | -430.3% |
| ROE % | 104.5% | - | 44.7% | 75.5% | -24.4% | -28.9% |
| ROCE % | 142.3% | - | -28.0% | -139.7% | -28.6% | -32.0% |
Shareholding Pattern
Insiders
2.65%
Institutions
107.78%
Public Float
110.72%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 13.33% | 4.18M | $32.51M |
| 2 | Alpha Wave Global, LP | 11.52% | 3.61M | $28.10M |
| 3 | FMR, LLC | 11.47% | 3.60M | $27.99M |
| 4 | Versant Venture Management, LLC | 8.47% | 2.66M | $20.67M |
| 5 | Blackrock Inc. | 6.30% | 1.98M | $15.38M |
| 6 | Squarepoint Ops LLC | 4.80% | 1.51M | $11.72M |
| 7 | Aberdeen Group plc | 3.69% | 1.16M | $8.99M |
| 8 | Franklin Resources, Inc. | 3.51% | 1.10M | $8.56M |
| 9 | Vanguard Capital Management LLC | 3.32% | 1.04M | $8.10M |
| 10 | 72 Investment Holdings, LLC | 3.25% | 1.02M | $7.92M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LENZ
No recent headlines available.